Literature DB >> 47950

Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction.

A N Bender, S P Ringel, W K Engel, M P Daniels, Z Vogel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 47950     DOI： 10.1016/s0140-6736(75)91886-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  36 in total

1.  A radioimmunoassay for the quantitative evaluation of anti-human acetylcholine receptor antibodies in myasthenia gravis.

Authors:  V M Monnier; B W Fulpius
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

Review 2.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

Review 3.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

4.  Accessibility to antibodies of acetylcholine receptors in the neuromuscular junction.

Authors:  A D Zurn; B W Fulpius
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

5.  Effects of autoantibodies to the insulin receptor on isolated adipocytes. Studies of insulin binding and insulin action.

Authors:  C R Kahn; K Baird; J S Filier; D B Jarrett
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

6.  Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.

Authors:  K V Toyka; K L Birnberger; A P Anzil; C Schlegel; U Besinger; A Struppler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154

7.  A case of myasthenia gravis treated with steroids: some suggestions for the mechanisms underlying their effect.

Authors:  P Dandona; E J Corkan; G E Sladen
Journal:  Postgrad Med J       Date:  1977-06       Impact factor: 2.401

8.  T and B lymphocytes in myasthenia gravis.

Authors:  Y Itoyama; S Kawanami; I Goto; Y Kuroiwa
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

9.  [Myasthenic syndrome during penicillamine treatment (author's transl)].

Authors:  F Schumm; M Stöhr
Journal:  Klin Wochenschr       Date:  1978-02-01

10.  Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.

Authors:  B Vernet-der Garabedian; J F Bach; E Morel
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.